AMLX Key Statistics, Chart & Performance
The current stock price of AMLX is 13.21 USD. In the past month the price increased by 21.97%. In the past year, price increased by 265.26%.
AMLX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to AMLX. When comparing the yearly performance of all stocks, AMLX is one of the better performing stocks in the market, outperforming 98.3% of all stocks.
AMLX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to AMLX. While AMLX has a great health rating, there are worries on its profitability.
AMLX Financial Highlights
Over the last trailing twelve months AMLX reported a non-GAAP Earnings per Share(EPS) of -1.8. The EPS increased by 2.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -41.15% | ||
| ROE | -44.96% | ||
| Debt/Equity | 0 |
AMLX Forecast & Estimates
16 analysts have analysed AMLX and the average price target is 20.63 USD. This implies a price increase of 56.14% is expected in the next year compared to the current price of 13.21.
For the next year, analysts expect an EPS growth of 36.76% and a revenue growth -100% for AMLX
AMLX Ownership
AMLX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.28 | 1.047T | ||
| JNJ | JOHNSON & JOHNSON | 20.6 | 564.909B | ||
| MRK | MERCK & CO. INC. | 22.13 | 293.697B | ||
| PFE | PFIZER INC | 8.86 | 152.263B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.8 | 117.3B | ||
| ZTS | ZOETIS INC | 18.47 | 55.835B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.47 | 25.214B | ||
| VTRS | VIATRIS INC | 5.66 | 16.539B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.99 | 12.123B | ||
| AXSM | AXSOME THERAPEUTICS INC | 221.96 | 9.353B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find more ETFs on the USA exchanges | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AMLX
Company Profile
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). The company is headquartered in Cambridge, Massachusetts and currently employs 123 full-time employees. The company went IPO on 2022-01-07. The firm is focused on three investigational therapies across several neurodegenerative and endocrine diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX0114 in amyotrophic lateral sclerosis (ALS). AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide.
Company Info
AMYLYX PHARMACEUTICALS INC
55 Cambridge Parkway, Suite 6W
Cambridge MASSACHUSETTS US
Employees: 123
Phone: 16176820917
AMYLYX PHARMACEUTICALS INC / AMLX FAQ
What does AMLX do?
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). The company is headquartered in Cambridge, Massachusetts and currently employs 123 full-time employees. The company went IPO on 2022-01-07. The firm is focused on three investigational therapies across several neurodegenerative and endocrine diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome and progressive supranuclear palsy (PSP), and AMX0114 in amyotrophic lateral sclerosis (ALS). AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide.
What is the stock price of AMYLYX PHARMACEUTICALS INC today?
The current stock price of AMLX is 13.21 USD. The price decreased by -4.83% in the last trading session.
What is the dividend status of AMYLYX PHARMACEUTICALS INC?
AMLX does not pay a dividend.
What is the ChartMill technical and fundamental rating of AMLX stock?
AMLX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Where is AMYLYX PHARMACEUTICALS INC (AMLX) stock traded?
AMLX stock is listed on the Nasdaq exchange.
What is the market capitalization of AMLX stock?
AMYLYX PHARMACEUTICALS INC (AMLX) has a market capitalization of 1.45B USD. This makes AMLX a Small Cap stock.
When does AMYLYX PHARMACEUTICALS INC (AMLX) report earnings?
AMYLYX PHARMACEUTICALS INC (AMLX) will report earnings on 2026-03-02, after the market close.